文献速递妇科

卵巢癌肿瘤微环境中新型免疫检查点靶点的动态分布

Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: A dynamic landscape.
PubMed 文献 · Gynecol Oncol · 2020-11-06

该研究对98例接受新辅助化疗(NACT)的上皮性卵巢癌(EOC)患者,在化疗前后进行IDO、PDL1、LAG3和TIM3免疫组化检测,阳性阈值设为5%。结果显示TIM3是最常见的共调节因子(>75%阳性),NACT显著改变免疫共调节因子的表达状态(>70%患者出现阴阳转换),但共表达模式与铂类敏感性及生存无关。

要点

  • TIM3是EOC中最丰富的共抑制分子,阳性率>75%,可能是有吸引力的靶点。
  • 超过半数卵巢肿瘤表达2种、3种甚至全部4种共抑制分子,支持免疫检查点抑制剂联合方案。
  • NACT显著改变免疫抑制分子表达,联合方案选择应适应化疗后免疫微环境组成。

核心结论

  • TIM3是卵巢癌中最丰富的共抑制分子,可能是有吸引力的靶点。
  • 卵巢癌常共表达2种或以上标志物,支持免疫检查点抑制剂联合策略。
  • NACT显著改变免疫抑制分子表达,提示联合方案应基于化疗后免疫微环境组成选择。

研究设计与样本

  • 研究纳入98例接受NACT的EOC患者,对化疗前后样本进行IDO、PDL1、LAG3和TIM3免疫组化检测。
  • 阳性判定阈值设为5%。

主要发现

  • TIM3是最常见的共调节因子,超过75%的样本为TIM3阳性。
  • 仅22%、28%和17%的样本分别为IDO、PDL1和LAG3阳性。
  • 超过半数卵巢肿瘤表达2种、3种甚至全部4种共抑制分子,但生物标志物之间无相关性。
  • NACT对免疫共调节因子表达有显著影响,超过70%患者出现生物标志物状态从阴性转为阳性或反之。
  • 铂类敏感与耐药患者的共调节因子表达模式无显著差异;多种抑制分子共表达未影响总生存和无进展生存。

临床怎么用

  • TIM3可作为卵巢癌免疫治疗的潜在靶点。
  • 免疫检查点抑制剂联合方案可考虑针对多种共表达标志物。
  • NACT后应重新评估免疫微环境组成以指导联合方案选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The disappointing activity of single agent immune-checkpoint inhibitors in epitherlial ovarian cancer (EOC) has been attributed in part to its unique tumor microenvironment (TME). IDO, PDL1, LAG3 and TIM3 have been implicated in the immunotolerance of EOC. We investigated the expression of these co-regulators, their change with neoadjuvant chemotherapy (NACT), and their association with outcome. METHOD: We identified 98 patients with EOC treated with NACT and performed IDO, PDL1, LAG3 and TIM3 immunohistochemistry on samples obtained before and after NACT. The cut-off threshold to consider a positive sample was set at 5%. RESULTS: In our cohort, TIM3 was the most prevalent co-regulator, with more than 75% of the samples being TIM3 positive. In comparison, only 22%, 28% and 17% of the samples were considered IDO, PDL1 and LAG3 positive. More than half of ovarian tumors expressed 2, 3 or even all 4 co-inhibitory molecules. However, biomarkers were not correlated with each other. NACT had a marked impact on immune co-regulator expression with over 70% of patients showing a change in biomarker status from negative to positive or vice versa. There was no significant difference in the pattern of co-regulator expression between platinum-sensitive and resistant patients. Co-expression of multiple inhibitory molecules did not appear to affect overall and progression-free survival. CONCLUSION: TIM3 is the most abundant co-inhibitory molecule in OC and may represent an attractive target. In addition, OC frequently co-expressed 2 or more markers supporting ICI combinatorial approaches. Finally, NACT significantly altered the expression of immunosuppressive molecules suggesting that the choice of ICI combinations should be adapted to the composition of the post-NACT immune TME.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Blanc-Durand F, Genestie C, Galende EY, et al. Distribution of novel immune-checkpoint targets in ovarian cancer tumor microenvironment: A dynamic landscape. Gynecol Oncol. 2020. PMID: 33162175. doi:10.1016/j.ygyno.2020.09.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。